Who
Teresa Marie Bitetti
President, OBU
Company insider
Files Form 4 as: President, OBU, Takeda Pharmaceutical Company; Director, Aura Biosciences; Director, Fusion Pharmaceuticals.
In numbers
- Trades disclosed
- 14
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $1.7M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 16 Oct 2023
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Sold | $855K50,012 at $17.10 | filing |
| 10 Aug 2026filed 12 Aug 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Sold | $855K50,012 at $17.10 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Code A | —43,886 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Code A | —43,886 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 27 Apr 2026filed 28 Apr 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Code A | —64,988 at $0.00 | filing |
| 27 Apr 2026filed 28 Apr 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Code A | —64,988 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,000 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 4 Jun 2024filed 4 Jun 2024 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —34,000 | filing |
| 16 Oct 2023filed 16 Oct 2023 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.